Information Provided By: 
Fly News Breaks for November 28, 2016
HZNP
Nov 28, 2016 | 08:40 EDT
BMO Capital analyst Gary Nachman says that the risk/reward ratio for Horizon is positive going into the Phase 3 data for its Actimmune drug in Friedreich's Ataxia. The analyst thinks that there is only a 50% chance that the data will be successful;. However, he says that the risk/reward ratio is "favorable," based on how he thinks the shares will perform in the wake of the event. He keeps a $29 price target and an Outperform rating on the shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
